Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 39,800 shares at $81.55 ($3.2M) on 2016-11-15, disclosed to the SEC on 2016-11-17.
Open-market sale of $3.2M RARE by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $79.39 | 1,414 | $112K | 3.5% |
| 2 | $79.39 | 1,414 | $112K | 3.5% |
| 3 | $80.64 | 6,451 | $520K | 16.1% |
| 4 | $80.64 | 6,451 | $520K | 16.1% |
| 5 | $81.55 | 7,755 | $632K | 19.5% |
| 6 | $81.55 | 7,755 |
| $632K |
| 19.5% |
| 7 | $82.36 | 4,180 | $344K | 10.6% |
| 8 | $82.36 | 4,180 | $344K | 10.6% |
| 9 | $83.01 | 200 | $17K | 0.5% |
| Total | $81.28 avg | 39,800 | $3.2M | 100% |
| Filing → |
| RARE | SELL | 2024-12-31 | $990K | — | Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |